The Science - - BioPharm International


The Science

BioPharm International

For example, human growth hormone was once available only from the pituitary glands of cadavers. It was very rare, expensive, and potentially contaminated with prions. In the 1980s, it even transmitted a rare neurological disease (Creutzfeld-Jakob disease) to patients before anyone was sure what kind of agent caused the disease. Now recombinant bacteria produce human growth hormone in large quantities that have made it safer and less expensive, and thus available to more patients around the world.

When those bacteria were genetically modified, the process had only just begun. They had to be cultivated in large enough numbers to produce therapeutic quantities of the protein. And that meant that it was essential to understand how they grew and reproduced.

Cell Metabolism

In broad outline, cell metabolism is basically the same in all living things. Oxygen and nutrients are brought inside the cell, where chemical reactions driven by proteins provide the cell with energy and raw materials. Waste products including water, carbon dioxide, and ammonia are expelled. These chemical facts of life point to three major concerns in fermentation and cell culture: nutrients, aeration, and the removal of waste products and heat. There are, however, some significant differences in the details of how different sorts of cells carry out the process of metabolism.

Bacteria, for instance, are prokaryotes, some of the oldest life forms on Earth. They are simple creatures, basically tiny capsules of watery cytoplasm in which float DNA and RNA, metabolic enzymes, food, and waste products. Prokaryote metabolism is relatively simple: They need simple nutrients (like sugar) to burn for energy.

Yeasts and plant and animal cells are a more complex form of life called eukaryotes. In eukaryotes, a nucleus protects the genetic material, which is stored on chromosomes. Ribosomes outside of the nucleus use RNA to translate that information for making proteins. Many other inclusion bodies or organelles are found inside the eukaryotic cell: microtubules, vacuoles, mitochondria, lysosomes, smooth and rough endoplasmic reticuli, ribosomes, and Golgi bodies.

In eukaryotic cells, mitochondria perform much of the metabolic work. They act just like little prokaryotes, employed by the big cell to do what they're best at: getting energy out of food.

Large nutrient molecules (such as proteins, polysaccharides, and fats) are broken down into smaller, usable pieces (amino acids, sugars, fatty acid, and glycerol). Those are broken down even further to make, among other things, two very important molecules: adenosine triphosphate (ATP) and nicotinamide adenine dinucleotide (NAD). Remaining nutrients are taken up by the mitochondria, which oxidize them to make more ATP and NAD.

ATP stores energy for all living things, and NAD is important in its production. ATP provides the power needed for most cell processes: molecular synthesis; transport of materials across the membrane; and cell replication, movement, and maintenance.

Cells for Bioproduction

Today's biotech and biopharmaceutical companies use a variety of bacterial, yeast, animal, and plant cells for production. The choice of which cell to use depends on a number of factors, some technical and some economic.

Bacteria and yeast, for instance, are relatively simple to grow. Each cell of a bacterium or yeast is an independent organism capable of its own metabolism. Yeasts and bacteria have fairly simple nutritional needs and grow well suspended in a liquid medium, even in big fermentors with a capacity of 1,000, 10,000, or more liters. The cell walls of bacteria and yeasts resist damage, even when the cells are packed closely together and stirred around by mechanical mixers.

blog comments powered by Disqus



FDA Panel Unanimously Backs Secukinumab for the Treatment of Psoriasis
October 22, 2014
Roche to Expand and Improve its Basel Site
October 22, 2014
Pall ForteBio Releases Bioprocessing Contamination Detection Kit
October 22, 2014
EMA Works to Speed Up Ebola Treatment
October 20, 2014
Amgen Sues Sanofi and Regeneron over Patent for mAb Targeting PCSK9
October 20, 2014
Author Guidelines
Source: BioPharm International,
Click here